Camizestrant + CDK4/6 inhibitor for the treatment of emergent ESR1 mutations during first-line endocrine-based therapy and ahead of disease progression in patients with HR+/HER2– advanced breast cancer: Phase 3, double-blind ctDNA-guided SERENA-6 trial

In the phase 3 SERENA-6 trial, camizestrant plus CDK4/6 inhibition guided by detection of ESR1 mutations in circulating tumor DNA during first-line aromatase inhibitor plus CDK4/6 inhibition in patients with HR+ HER2- advanced breast cancer resulted in a statistically significant and clinically meaningful improvement in progression-free survival.